R&D News | pharmaphorum

News

AZ halts development of Beta variant COVID-19 vaccine

AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted at the Beta variant of the virus, which started developme

News

FDA fast tracks Bayer's oral anticoagulant asundexian

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

News

RedHill's oral drug boosts Veklury efficacy in severe COVID

An oral drug developed by RedHill Biopharma has reduced mortality in severe COVID-19 patients when added to therapy with corticosteroids and Gilead Science's intravenous antiviral Veklury,

News

Astellas says Pompe gene therapy clears safety hurdle

With the safety of gene therapies thrown into the spotlight by a series of FDA clinical holds, Astellas has said that an interim readout in a phase 1/2 trial of its Pompe disease candidate

News

Bayer's pipeline takes a hit as it drops eliapixant

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds.

News

UCB preps filings for another challenger to AZ's Soliris

Belgian drugmaker UCB says it will be able to file not one but two new drug therapies for autoimmune disease generalised myasthenia gravis (gMG) this year, after its C5 inhibitor zilucoplan

AZ halts development of Beta variant COVID-19 vaccine

FDA fast tracks Bayer's oral anticoagulant asundexian

RedHill's oral drug boosts Veklury efficacy in severe COVID

Astellas says Pompe gene therapy clears safety hurdle

Bayer's pipeline takes a hit as it drops eliapixant

UCB preps filings for another challenger to AZ's Soliris

Danco fights back after US court curbs abortion pill access

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks